The IJTLD
The IJTLD is the leading peer-reviewed journal dedicated to lung health worldwide.
We welcome submissions on basic, translational, clinical, epidemiological and programmatic research relevant to the Union’s mission to find health solutions for these conditions.
Public Health Action
Public Health Action aims to disseminate the latest operational research on health systems, public health and disease control.
We have recently expanded the scope of PHA to provide coverage of relevant areas of the UN's Sustainable Development Goals (SDGs).
IJTLD Open
Launched in January 2024, IJTLD Open is The Union's new Open Access journal for the latest research on TB and lung diseases including asthma, COVID-19 and COPD.
We welcome submissions on the development of diagnostics and treatments for the prevention, management and control of respiratory diseases.
Fast-Track Articles
In order to share scientific research of immediate concern as rapidly as possible, The Union is fast-tracking the publication of certain accepted articles from the IJTLD and PHA and publishing them in full on our website, prior to their publication in the Journals. Read fast-track articles:
The 100th anniversary of bacille Calmette-Guérin (BCG) and the latest vaccines against COVID-19
On 18th July 2021, we celebrate the 100th anniversary of the first use of the BCG vaccine for TB. An Editorial in IJTLD discusses BCG’s efficacy, heterologous protection and controversial link with COVID-19. The preprint is free to read.
Call to action for an invigorated drive to scale up TB prevention
An Editorial for IJTLD highlights the importance of TB preventive treatment (TPT) and the launch by WHO, governments, civil society and other partners of a ‘Call to Action’ for broader access to TPT for those in need. The article is free to read.
Impact of COVID-19 on TB detection in the private sector in Nepal
In this Correspondence accepted article for IJTLD, the authors found a 67.4% decrease in testing, a 66.9% decrease in bacteriologically confirmed (bac+) diagnosis and a 58.9% decrease in diagnosis of all forms TB. The preprint is free to read.